Back to the fundamentals: Frazier rolls out $1B fund to ramp up a new slate of biotech startups

Paul Schloesser

Associate Editor

Less than a year after Frazier Healthcare Partners debuted an $830 million public fund for life science investments, the VC is back with even more cash — with a focus on early biotechs in tow.

The VC’s life sciences unit announced early Wednesday that it officially closed its 4th dedicated fund, beating out its original goal of $800 million by over 20% and ending at $987 million. The fund, called FLS XI, will be led by a few partners: managing partners Patrick Heron and James Topper alongside general partner Dan Estes. As for core strategies, company creation and spinouts will be one of the main focuses.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Back to the fundamentals: Frazier rolls out $1B fund to ramp up a new slate of biotech startups

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Back to the fun­da­men­tals: Fra­zier rolls out $1B fund to ramp up a new slate of biotech star­tups

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Back to the fundamentals: Frazier rolls out $1B fund to ramp up a new slate of biotech startups

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir